BioCentury
ARTICLE | Emerging Company Profile

Hangzhou Highlightll: Twice the target, hold the tox

TYK2/JAK1 inhibitor could treat a broad range of autoimmune diseases

July 3, 2021 2:04 AM GMT
Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article